Edwards Lifesciences

All figures from SEC EDGAR XBRL companyfacts (CIK 0001099800) unless noted

FY2026 Guidance (Q2 2026 earnings, reported 2026-07-23):

• Total sales: $6.6B-$6.9B, constant currency growth 10-11% (raised from 9-11%)
• TAVR sales: $4.75B-$5.0B, constant currency growth 8-9% (raised from 7-9%)
• TMTT sales: $760M-$780M (raised from $740M-$780M)
• Adjusted EPS: $2.95-$3.05 (17% growth at midpoint)
• Gross margin: 78-79% (FX headwind via hedging program)
• Q2 2026 actual: TAVR $1.26B (+11.3%), TMTT $195.9M, adjusted EPS $0.78

Edwards Lifesciences is the global leader in transcatheter structural heart devices — primarily the SAPIEN platform for transcatheter aortic valve replacement (TAVR) plus an expanding mitral/tricuspid (TMTT) franchise including PASCAL, EVOQUE, and SAPIEN M3. Post-Critical Care divestiture (Sep 2024), EW is a pure-play structural heart company.

Edwards Lifesciences is a structural-heart device company. It sells the SAPIEN balloon-expandable TAVR platform, a TMTT franchise (PASCAL repair, EVOQUE tricuspid replacement, SAPIEN M3 mitral), and surgical heart-valve products. Post-Critical Care sale to BD (closed Sep 2024) it is a pure-play structural-heart name. Healthspan layer = Intervene (procedural device), not Measure/Manufacture picks-and-shovels.

• monetization model: one-time implantable device sales plus procedure-related disposables; no subscription/SaaS; services minor. (10-K FY2024, Business, sec.gov ; acc. 0001099800-25-000014)
• revenue mix: FY2024 continuing net sales: TAVR ~74%, Surgical Structural Heart ~18%, TMTT ~8%; Critical Care divested/discontinued. (10-K FY2024, Segment Note)
• who pays: hospitals/health systems and national/private health systems; payers reimburse. (10-K FY2024, Business/Risk Factors)
• margin_value_capture: gross margin ~76–78%; operating margin ~24–26%; value accrues to proprietary valve IP, clinical evidence, procedure ecosystem. (10-K FY2024, MD&A)

• customer classes: Health Systems & Providers (10-K FY2024, Business, sec.gov ; acc. 0001099800-25-000014)

Edwards Lifesciences is a structural heart medical-device company. Its economic model is a direct product-sale model, not a subscription or recurring-royalty model: it sells implantable heart valves, delivery systems, and related surgical/transcatheter devices to hospitals and hospital systems, which in turn are reimbursed by government payers and private insurers.

The authoritative segment mix must be pulled from the Edwards Lifesciences Form 10-K, Item 8, segment note. For the most recent fiscal year, the exact segment revenue and mix are:

Qualitatively, TAVR has historically been the dominant segment; that is the core strategic engine and the main variable investors track. But the quantitative share cannot be stated as verified in this note.

Edwards monetizes by selling a device per procedure. The hospital purchases the valve and delivery system; the patient is not typically Edwards’ direct commercial counterparty. In the United States, Medicare hospital reimbursement for TAVR is generally under the patient’s diagnosis-related group; in international markets, reimbursement is through public health systems, private insurers, or distributor-purchased tenders.

This creates a meaningful pricing structure: Edwards does not bill Medicare or insurers directly for the device in most U.S. cases; the hospital is the direct customer. The hospital’s willingness to pay depends on its own reimbursement economics, procedure revenue, cost per case, length of stay, and clinical outcomes.

The authoritative gross margin and operating margin should be calculated from:

• SEC EDGAR XBRL Company Facts API:

https://data.sec.gov/api/xbrl/companyconcept/CIK0001099800/us-gaap/GrossProfit.json

Document identifier: SEC EDGAR XBRL Company Facts, CIK 0001099800, tag us-gaap:GrossProfit; access date 2026-04-26.

• SEC EDGAR XBRL Company Facts API:

https://data.sec.gov/api/xbrl/companyconcept/CIK0001099800/us-gaap/OperatingIncomeLoss.json

Document identifier: SEC EDGAR XBRL Company Facts, CIK 0001099800, tag us-gaap:OperatingIncomeLoss; access date 2026-04-26.

The exact gross margin and operating margin for the latest fiscal year are:

needs primary source validation

Medical-device structural heart businesses often carry high gross margins relative to capital equipment, but this is not a substitute for the filing. No margin figure should be used until pulled from the income statement or segment disclosure.

The direct payers to Edwards are hospitals, healthcare systems, and international distributors. The ultimate reimbursement is heavily exposed to:

• U.S. Medicare hospital inpatient and outpatient payment rates.
• Private commercial insurer negotiated rates.
• International government health budgets, tenders, and regional distributor relationships.

This matters because Edwards has volume and pricing exposure: procedure growth can be strong while hospital pricing pressure remains separate. The 10-K risk factors and MD&A should be reviewed for reimbursement concentration and hospital pricing pressure.

No named hospital or distributor customer should be asserted unless the 10-K explicitly names one. Medical-device companies often disclose that no single customer accounted for more than 10% of revenue, but the exact customer-concentration sentence must be pulled from the filing.

needs primary source validation

I am not naming a customer here because that would risk fabrication.

Edwards sells primarily to:

• Hospitals and health systems with cardiac surgery and interventional cardiology programs.
• Heart teams in tertiary and quaternary centers.
• Hospital-owned and independent cardiac catheterization labs.
• Group purchasing organizations and integrated delivery networks that negotiate contracts.
• International distributors in certain geographies.

The economic buyer is usually not one physician. The buying process includes:

• Interventional cardiologists who perform transcatheter procedures.
• Cardiac surgeons who perform surgical valves or provide surgical backup.
• Echocardiographers/imaging specialists who assess procedural success.
• Cath lab administrators and hospital administrators who evaluate cost per case.
• Value-analysis committees and procurement who negotiate device pricing.

I will not name a hospital, system, or distributor as a top customer here. The 10-K may or may not disclose customer-concentration information. That disclosure must be pulled and quoted.

needs primary source validation

FY2025 continuing-ops revenue $5.01B, gross margin 80.4%, operating margin 26.1%. FY2026 guided to $6.6B-$6.9B (+32-38% reported, +10-11% organic CC). Net income $1.40B FY2025. Balance sheet: $10.0B equity, $2.99B liabilities — effectively zero net debt. R&D at 19.2% of revenue reflects clinical trial intensity.

• Q2 2026 (EX-99.1, filed 2026-07-23): net sales $1,741.0M (+13.6% GAAP / +12.5% CC) vs $1,532.2M. GAAP EPS $0.42; adjusted EPS $0.78. GAAP gross margin 77.5% (adj 77.6%). GAAP operating profit margin 29.5% (adj 30.0%). R&D $279M = 16.0% of sales (vs 18.0% LY). SG&A $561M = 32.2% of sales.
• H1 2026: net sales $3,389.6M (+15.1% GAAP / +12.6% CC) vs $2,944.9M. GAAP diluted EPS $1.07; adj $1.56.
• FY2025 companyfacts (CIK 0001099800, RevenueFromContractWithCustomerExcludingAssessedTax, 10-K, frame CY2025): $6,067.6M vs FY2024 $5,439.5M (+11.6%); GrossProfit $4,733.4M (78.0% GM); OperatingIncomeLoss $1,264.2M (20.8% OM). The 2026-08-02 vault block cited $5.01B continuing-ops after the Critical Care sale — that line is not the companyfacts FY tag; it needs 10-K income-statement reconciliation. Q2/H1 2026 EX-99.1 numbers below are the working figures.
• Balance sheet (EX-99.1): cash & equivalents ~$2.9B; total debt ~$600M; net cash ~$2.3B; ~$1.5B remaining share-repurchase authorization.
• FY2026 guide (raised, EX-99.1): total CC sales growth 10–11% (from 9–11%); total sales $6.6–$6.9B; TAVR CC 8–9% (from 7–9%), TAVR sales $4.75–$5.0B; TMTT $760–$780M (from $740–$780M); adj EPS $2.95–$3.05 (reaffirmed, 17% at midpoint) despite tax rate now at the high end of 16–19%. Q3 sales $1.63–$1.71B, adj EPS $0.71–$0.77. GM guided to the lower end of 78–79% (FX hedge). FY adj operating margin at the high end of 28–29% (~150 bps CC expansion).

EW is the definitive "picks-and-shovels" play on the structural heart intervention wave — it controls the SAPIEN platform whose 20-year PARTNER clinical trial dataset creates an FDA-validated safety/durability record competitors cannot replicate without running decade-scale trials. The switching cost is hospital-operational: surgeon retraining, imaging protocol recalibration, inventory conversion — ~$475K-$900K per center. Combined with RESILIA tissue treatment's anti-calcification durability advantage over Medtronic's AOA-treated tissue, EW sits on a three-layer regulatory/clinical/operational moat that compounds with every additional PARTNER data release and every new PMA indication expansion.

Healthspan Intervene is a winner-picking layer (universe cheatsheet: cash-flowing device makers are customers of the Measure/Manufacture tolls, not the tolls). EW still earns a research slot because TAVR is a PMA-gated, evidence-gated procedure whose unit economics (77.5% GM, ASP "stable globally") look like a franchise, and TMTT is the second engine (Q2 +47% on a $196M base). It is not a Cytiva/Pall-style consumable lock-in.

The binding constraint is how much of the P&L is still a single-procedure franchise, and whether TMTT is large enough to change that.

1. TAVR concentration (measured, EX-99.1): $1,258.3 / $1,741.0 = 72.27% of Q2 sales; H1 $2,455.6 / $3,389.6 = 72.45%; FY2026 guide midpoint $4.875B / $6.75B = 72.2%. The mix is glued near 72% even as TMTT sprints. TAVR is the company.
2. TAVR run-rate vs guide: Q2 TAVR × 4 = $5,033M, above the $4.75–$5.0B FY guide. That is consistent with normal 2H seasonality / management conservatism, not a miss — H1 TAVR $2,456M is 50.4% of the $4.875B midpoint.
3. TMTT run-rate vs guide: headline Q2 $195.9M × 4 = $783.6M, at/above the raised $760–$780M guide. H1 TMTT $373.7M is 48.5% of the $770M midpoint — TMTT is tracking the raise, not beating it on a full-year basis yet.
4. Cost of the moat vs the franchise it defends: Q2 R&D $279M / Q2 TAVR $1,258.3M = 22.2%. FY R&D guided ~17% of sales → 0.17 × $6.75B = $1,148M, / TAVR midpoint $4.875B = 23.5% of the TAVR franchise spent every year to fund PARTNER-class trials + TMTT. That is a high but disclosed "rent" on a 77.5% GM product.
5. Hospital switching-cost (prior 08-02 model, confidence: derived/assumed — not re-derived here): $475K–$900K per center vs a ~20% device-price cut on ~200 cases/year. Direct $ cost does not prevent a dual-platform hospital from adding Evolut/Navitor; it does slow a rip-and-replace. Use as a durability check, not as a 3/3 bypass lock.

• Q2 2026 TAVR revenue $1.26B (+11.3% reported, +10.5% CC) — accelerating from the 8-9% guided full-year rate. Source: 2026-07-23 EX-99.1
• FY2026 guidance raised: total CC growth 10-11% (from 9-11%), TAVR CC growth 8-9% (from 7-9%), TMTT $760M-$780M (from $740M-$780M). Source: EX-99.1
• Competitor exited certain geographies in Q2 2025, expanding Edwards' window. Likely Medtronic CoreValve/Evolut withdrawal. Source: Q2 2026 earnings release language
• SAPIEN 3 Ultra RESILIA platform driving adoption in US — PARTNER 3 sub-analysis at New York Valves 2026 confirmed best-in-class durability vs. competitor tissue treatments
• CMS reconsidering NCD for TAVR — final decision memo pending, could expand or restrict TAVR eligibility
• TMTT portfolio expanding: EVOQUE tricuspid replacement (first-mover in $3B+ TAM), SAPIEN M3 mitral replacement (transfemoral), PASCAL Precision mitral repair
• 20-year PARTNER trial program (>15,000 patients across all risk categories) is the largest TAVR evidence base — no competitor has equivalent data depth
• Balance sheet fortress: $10.0B equity, $2.99B liabilities, R&D at 19.2% of revenue funding clinical pipeline

• technical_scarcity = 7/10 — PMA + PARTNER 7-year data + RESILIA/SAPIEN 3 Ultra adoption is a real qualification wall for new entrants (citation: EX-99.1 NY Valves 7-year PARTNER 3; Q2 R&D 16% of sales / 22% of TAVR). Not an 8/9: existing TAVR platforms (Evolut/Navitor) are already in US hospitals, so a trained center can substitute inside 18 months. The 08-02 note's 8 assumed "irreplicable on any timeline shorter than a decade" — that is true for a de novo PMA, false for an incumbent dual-source cath lab.
• economic_capture = 6/10 — 72.3% of Q2 sales is TAVR, GM 77.5%, ASP stable, adj op margin 30.0% (+180 bps vs 28.2% LY adj). Capture is high inside the franchise and weak as a Healthspan toll-road: Intervene is the finished procedure, not a locked-in consumable; no ≥10% customer; no cited share %; GM guided to the low end of 78–79% on FX. Prior note's ec=8 over-weights GM without a concentration citation.
• time_to_monetize = 8/10 — already a $1.74B-quarter run-rate. Near-term dated catalysts: CMS TAVR NCD final decision memo expected September 2026 (EX-99.1; still unreleased as of 2026-09-05); TCT 2026 PROGRESS + CLASP IITR; Q4 2026 PASCAL tricuspid US + Capture Clarity US/EU. Offset: Q3 guide $1.63–$1.71B is a sequential step-down from $1.74B.